Pomerantz Law Firm Announces Class Action Against Replimune Group for Investor Losses

Class Action Lawsuit against Replimune Group, Inc.

On September 18, 2025, Pomerantz LLP, a respected law firm, announced the initiation of a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL). This suit has arisen from losses experienced by investors related to their holdings in Replimune securities. As per the information released by the firm, individuals who have incurred losses are urged to contact Danielle Peyton via email at [email protected] or through the firm's hotline at 888-4-POMLAW, Ext. 7980. Investors are encouraged to provide their contact details and share the number of shares acquired to assist in the lawsuit process.

The central issue of this class action revolves around allegations that Replimune and its executives may have committed securities fraud or engaged in other unlawful corporate activities. Investors have until September 22, 2025, to seek court approval as Lead Plaintiff if they purchased Replimune securities during the class period. Interested investors can access the complaint and more details through Pomerantz's website.

Background of Replimune Group, Inc.

Replimune Group is known for its innovative approaches in the biotechnology sector, particularly in developing treatments for various forms of cancer. Their pipeline includes RP1, a candidate for advanced melanoma treatment, which has been subject to scrutiny recently. On July 22, 2025, the firm announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 in conjunction with nivolumab. The FDA's response indicated that the current application could not be approved due to inadequacies in the clinical trial data, specifically concerning the IGNYTE trial's control measures and patient population difficulties. Notably, the FDA did not raise any immediate safety concerns with the product but pointed out areas that need revision before any approval could be granted.

Market Impact

In the wake of this announcement, Replimune's stock suffered a significant decline, plummeting by 77.24%, or $9.52 per share, closing at just $2.81. This monumental drop not only reflects investor panic amid the FDA's response but also signals potential underlying issues with the company’s business practices as highlighted in the class action lawsuit.

The Role of Pomerantz LLP

Pomerantz LLP, noted for its expertise in corporate and securities law, has a historical precedent in driving high-stakes class action lawsuits. The firm's founder, Abraham L. Pomerantz, is known for paving the way in securities litigation, and Pomerantz LLP continues to uphold this legacy by advocating for victims of corporate misconduct. Over its extensive history, the firm has successfully orchestrated multiple multimillion-dollar settlements on behalf of affected investors, making them a formidable player in the legal landscape surrounding investor rights.

Conclusion

As the allegations unfold, concerned investors should remain informed and proactive regarding their legal rights in this matter. Those left vulnerable by the potential fraud allegations against Replimune Group may find some measure of recourse through this class action lawsuit, spearheaded by the capable Pomerantz law firm. Time is of the essence, as the deadline to engage in this legal pursuit approaches, and investors are strongly encouraged to act swiftly to safeguard their interests.